Evaxion Biotech AS (EVAX)
1.49
+0.12
(+8.76%)
USD |
NASDAQ |
Nov 22, 16:00
1.42
-0.07
(-4.70%)
After-Hours: 20:00
Evaxion Biotech Revenue (TTM): 3.295M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.295M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
3.295M
Minimum
Sep 2024
3.295M
Maximum
Sep 2024
3.295M
Average
3.295M
Median
Sep 2024
Revenue (TTM) Benchmarks
| Ascendis Pharma AS | 354.82M |
| DBV Technologies SA | -- |
| Adaptimmune Therapeutics PLC | 175.04M |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals PLC | -- |